As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…

08/01/2019 Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca…